Origins and Effects of Extracellular α-synuclein: Implications in Parkinson’s Disease (original) (raw)

References

• Ahn, K. J., Paik, S. R., Chung, K. C., & Kim, J. (2006). Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. Journal of Neurochemistry, 97, 265–279.
  Article PubMed CAS Google Scholar
• Albani, D., Peverelli, E., Rametta, R., Batelli, S., Veschini, L., Negro, A., et al. (2004). Protective effect of TAT-delivered alpha-synuclein: Relevance of the C-terminal domain and involvement of HSP70. FASEB Journal, 18, 1713–1715.
  PubMed CAS Google Scholar
• Bodles, A. M., Guthrie, D. J., Harriott, P., Campbell, P., & Irvine, G. B. (2000). Toxicity of non-Abeta component of Alzheimer’s disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. European Journal of Biochemistry, 267, 2186–2194.
  Article PubMed CAS Google Scholar
• Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., et al. (2000). Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects. Neuroscience Letters, 287, 65–67.
  Article PubMed CAS Google Scholar
• Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., & Del Tredici, K. (2004). Stages in the development of Parkinson’s disease-related pathology. Cell & Tissue Research, 318, 121–134.
  Article Google Scholar
• Caughey, B. (2000). Transmissible spongiform encephalopathies, amyloidoses and yeast prions: Common threads? Nature Medicine, 6, 751–754.
  Article PubMed CAS Google Scholar
• Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., et al. (2004). Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet, 364, 1167–1169.
  Article PubMed CAS Google Scholar
• Cohlberg, J. A., Li, J., Uversky, V. N., & Fink, A. L. (2002). Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry, 41, 1502–1511.
  Article PubMed CAS Google Scholar
• Conway, K. A., Lee, S.-J., Rochet, J. C., Ding, T. T., Williamson, R. E., & Lansbury Jr., P. T. (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: Implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America, 97, 571–576.
  Article PubMed CAS Google Scholar
• Du, H. N., Tang, L., Luo, X. Y., Li, H. T., Hu, J., Zhou, J. W., et al. (2003). A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry, 42, 8870–8878.
  Article PubMed CAS Google Scholar
• El-Agnaf, O. M., Jakes, R., Curran, M. D., Middleton, D., Ingenito, R., Bianchi, E., et al. (1998). Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Letters, 440, 71–75.
  Article PubMed CAS Google Scholar
• El-Agnaf, O. M., Salem, S. A., Paleologou, K. E., Cooper, L. J., Fullwood, N. J., Gibson, M. J., et al. (2003). Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB Journal, 17, 1945–1947.
  PubMed CAS Google Scholar
• El-Agnaf, O. M., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., et al. (2006). Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB Journal, 20, 419–425.
  Article PubMed CAS Google Scholar
• Fahn, S., & Sulzer, D. (2004). Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx, 1, 139–154.
  Article PubMed Google Scholar
• Fevrier, B., & Raposo, G. (2004). Exosomes: Endosomal-derived vesicles shipping extracellular messages. Current Opinion in Cell Biology, 16, 415–421.
  Article PubMed CAS Google Scholar
• Forloni, G., Bertani, I., Calella, A. M., Thaler, F., & Invernizzi, R. (2000). Alpha-synuclein and Parkinson’s disease: Selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Annals of Neurology, 47, 632–640.
  Article PubMed CAS Google Scholar
• Forno, L. S. (1996). Neuropathology of Parkinson’s disease. Journal of Neuropathology and Experimental Neurology, 55, 259–272.
  PubMed CAS Google Scholar
• Fortin, D. L., Nemani, V. M., Voglmaier, S. M., Anthony, M. D., Ryan, T. A., Edwards, R. H. (2005). Neural activity controls the synaptic accumulation of {alpha}-synuclein. Journal of Neuroscience, 25, 10913–10921.
  Article PubMed CAS Google Scholar
• Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., et al. (2005). The E46K mutation in alpha-synuclein increases amyloid fibril formation. Journal of Biological Chemistry, 280, 7800–7807.
  Article PubMed CAS Google Scholar
• Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin, T. M., & Subramaniam, V. (2002). Dependence of alpha-synuclein aggregate morphology on solution conditions. Journal of Molecular Biology, 322, 383–393.
  Article PubMed CAS Google Scholar
• Ibanez, P., Bonnet, A. M., Debarges, B., Lohmann, E., Tison, F., Pollak, P., et al. (2004). Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet, 364, 1169–1171.
  Article PubMed CAS Google Scholar
• Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., et al. (2004). Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. Journal of Biological Chemistry, 279, 46363–46366.
  Article PubMed CAS Google Scholar
• Kim, Y. S., Laurine, E., Woods, W., & Lee, S. J. (2006). A novel mechanism of interaction between alpha-synuclein and biological membranes. Journal of Molecular Biology, 360, 386–397.
  Article PubMed CAS Google Scholar
• Klegeris, A., Giasson, B. I., Zhang, H., Maguire, J., Pelech, S., & McGeer, P. L. (2006). Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB Journal, 20, 2000–2008.
  Article PubMed CAS Google Scholar
• Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nature Genetics, 18, 106–108.
  Article PubMed CAS Google Scholar
• Lee, E. N., Cho, H. J., Lee, C. H., Lee, D., Chung, K. C., & Paik, S. R. (2004). Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. Biochemistry, 43, 3704–3715.
  Article PubMed CAS Google Scholar
• Lee, H. J., Patel, S., & Lee, S. J. (2005). Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. Journal of Neuroscience, 25, 6016–6024.
  Article PubMed CAS Google Scholar
• Lee, P. H., Lee, G., Park, H. J., Bang, O. Y., Joo, I. S., & Huh, K. (2006). The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. Journal of Neural Transmission, 113, 1435–1439.
  Article PubMed CAS Google Scholar
• Lowe, R., Pountney, D. L., Jensen, P. H., Gai, W. P., & Voelcker, N. H. (2004). Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Science, 13, 3245–3252.
  Article PubMed CAS Google Scholar
• Maries, E., Dass, B., Collier, T. J., Kordower, J. H., & Steece-Collier, K. (2003). The role of alpha-synuclein in Parkinson’s disease: Insights from animal models. Nature Reviews Neuroscience, 4, 727–738.
  Article PubMed CAS Google Scholar
• Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., et al. (2005). Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron, 46, 857–868.
  Article PubMed CAS Google Scholar
• Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., et al. (2006). Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science, 313, 1781–1784.
  Article PubMed CAS Google Scholar
• Nickel, W. (2003). The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. European Journal of Biochemistry, 270, 2109–2119.
  Article PubMed CAS Google Scholar
• Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276, 2045–2047.
  Article PubMed CAS Google Scholar
• Seo, J. H., Rah, J. C., Choi, S. H., Shin, J. K., Min, K., Kim, H. S., et al. (2002). Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB Journal, 16, 1826–1828.
  PubMed CAS Google Scholar
• Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). alpha-Synuclein locus triplication causes Parkinson’s disease. Science, 302, 841.
  Article PubMed CAS Google Scholar
• Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., Goedert, M. (1998). alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proceedings of the National Academy of Sciences of the United States of America, 95, 6469–6473.
  Article PubMed CAS Google Scholar
• Sung, J. Y., Kim, J., Paik, S. R., Park, J. H., Ahn, Y. S., & Chung, K. C. (2001). Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. Journal of Biological Chemistry, 276, 27441–27448.
  Article PubMed CAS Google Scholar
• Sung, J. Y., Park, S. M., Lee, C. H., Um, J. W., Lee, H. J., Kim, J., et al. (2005). Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. Journal of Biological Chemistry, 280, 25216–25224.
  Article PubMed CAS Google Scholar
• Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., et al. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochemical and Biophysical Research Communications, 349, 162–166.
  Article PubMed CAS Google Scholar
• Volles, M. J., & Lansbury Jr., P. T. (2003). Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease. Biochemistry, 42, 7871–7878.
  Article PubMed CAS Google Scholar
• Volles, M. J., Lee, S.-J., Rochet, J. C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., et al. (2001). Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry, 40, 7812–7819.
  Article PubMed CAS Google Scholar
• Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of Neurology, 55, 164–173.
  Article PubMed CAS Google Scholar
• Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., et al. (2005). Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson’s disease. FASEB Journal, 19, 533–542.
  Article PubMed CAS Google Scholar

Download references